Compositions for inhibiting MASP-2 dependent complement activation
The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
1. A nucleic acid encoding complementarity determining regions (CDRs) of heavy and light chain variable regions of an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO:21 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:25 or SEQ ID NO:27.
2. The nucleic acid of claim 1 , wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO:25.
3. The nucleic acid of claim 1 , wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO:27.
4. A nucleic acid comprising a nucleotide sequence encoding heavy and light chain variable regions of an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO:21 and the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:25 or SEQ ID NO:27.
5. The nucleic acid of claim 4 , wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:25.
6. The nucleic acid of claim 4 , wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:27.
7. An expression vector comprising the nucleic acid according to claim 1 or claim 4 .
8. A cell comprising the expression vector according to claim 7 .
9. A method for producing an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, the method comprising culturing the cell of claim 8 under conditions and for a time sufficient to allow expression by the cell of the antibody, or antigen-binding fragment thereof, encoded by the nucleic acid.
10. The method of claim 9 , further comprising isolating the antibody, or antigen-binding fragment thereof.
11. A cell comprising:
(a) a nucleic acid encoding complementarity determining regions (CDRs) of a heavy chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, wherein the heavy chain variable region comprises the amino acid sequence set forth in SEQ ID NO:21; and
(b) a nucleic acid encoding complementarity determining regions (CDRs) of a light chain variable region of an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, wherein the light chain variable region comprises the amino acid sequence set forth in SEQ ID NO:25 or SEQ ID NO:27.
12. A method for producing an antibody, or antigen-binding fragment thereof, that binds to human MASP-2, the method comprising culturing the cell of claim 11 under conditions and for a time sufficient to allow expression by the cell of the antibody, or antigen-binding fragment thereof, encoded by the nucleic acid.
13. The method of claim 12 , further comprising isolating the antibody, or antigen-binding fragment thereof.